IP Library Granted Patent US 9,763,925
Granted Patent B2
US 9,763,925 · App. 15/064,137 · Granted Sep 19, 2017

Antibacterial compounds

Inventors: Francis Xavier Wilson (Abingdon, GB); Peter David Johnson (Abingdon, GB); Richard Vickers (Abingdon, GB); Richard Storer (Abingdon, GB); Graham Michael Wynne (Abingdon, GB); Alan Geoffrey Roach (Abingdon, GB); Olivier De Moor (Abingdon, GB); Colin Richard Dorgan (Abingdon, GB); Paul James Davis (Abingdon, GB)
Assignee: SUMMIT THERAPEUTICS PLC
A61K31/444A61K31/4439C07D235/18C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,763,925
App. No.
15/064,137
Granted
Sep 19, 2017
Kind
B2
Abstract

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Claims (7)

1. A method of treating Clostridium difficile -associated disease (CDAD) in a subject in need thereof, the CDAD selected from the group consisting of diarrhoea caused by Clostridium difficile , bloating caused by Clostridium difficile , flu-like symptoms caused by Clostridium difficile , fever caused by Clostridium difficile , appetite loss caused by Clostridium difficile , abdominal pain caused by Clostridium difficile , nausea caused by Clostridium difficile , dehydration caused by Clostridium difficile , colitis caused by Clostridium difficile and pseudomembraneous colitis caused by Clostridium difficile , which method comprises administering to said subject an effective amount of the compound 2,2′-di(pyridin-4-yl)-1H,1H-5,5′-bibenzo[d]imidazole, or a pharmaceutically acceptable N-oxide, salt, hydrate or solvate thereof.

2. The method of claim 1 , wherein the method comprises administering to said subject an effective amount of the compound 2,2′-di(pyridin-4-yl)-1H,1H-5,5′-bibenzo[d]imidazole.

3. The method of claim 1 , wherein the method comprises administering to said subject an N-oxide of the compound 2,2′-di(pyridin-4-yl)-1H,1H-5,5′-bibenzo[d]imidazole.

4. The method of claim 1 , wherein the method comprises administering to said subject a salt of the compound 2,2′-di(pyridin-4-yl)-1H,1H-5,5′-bibenzo[d]imidazole.

5. The method of claim 1 , wherein the method comprises administering to said subject a solvate of the compound 2,2′-di(pyridin-4-yl)-1H,1H-5,5′-bibenzo[d]imidazole.

6. A composition comprising an N-oxide of 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole.

7. A pharmaceutical composition comprising an antibacterial effective amount against Clostridium difficile of an N-oxide of 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: SUMMIT THERAPEUTICS PLC
To: SUMMIT (OXFORD) LIMITED
Reel/Frame 044859/0983 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 037947 FRAME 0899. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 8, 2016
From: WILSON, FRANCIS XAVIER; JOHNSON, PETER DAVID; VICKERS, RICHARD; STORER, RICHARD; WYNNE, GRAHAM MICHAEL; ROACH, ALAN GOEFFREY; DE MOOR, OLIVIER; DORGAN, COLIN RICHARD; DAVIS, PAUL JAMES
To: SUMMIT THERAPEUTICS PLC
Reel/Frame 039289/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2016
From: WILSON, FRANCIS XAVIER; JOHNSON, PETER DAVID; VICKERS, RICHARD; STORER, RICHARD; WYNNE, GRAHAM MICHAEL; ROACH, ALAN GEOFFREY; DE MOOR, OLIVIER; DORGAN, COLIN RICHARD; DAVIS, PAUL JAMES
To: SUMMIT THERAPEUTICS PLC
Reel/Frame 037947/0899 →
Priority Claims (1)
GB 0821913.3 · Dec 2, 2008 · national
Continuity (3)
Continuation 14616006 · Feb 6, 2015
Continuation 13131469
Related Publication 20160184283A1 · Jun 30, 2016